Therapy for Patients with Previously Treated Metastatic Colorectal Cancer (mCRC): Your Patient's Journey

INDICATION STIVARGA is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.